SEC Form 4 · accession 0001735276-18-000079
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Maraganore
Officer — Chief Executive Officer · Director
Period of report
Nov 21, 2018
Accepted (ET)
Nov 26, 2018 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2018 | M | 98,636 | $21.35 | A | 249,933 | D | |
| Common Stock | Nov 21, 2018 | F | 59,940 | $72.68 | D | 189,993 | D | |
| Common StockF2 | Oct 18, 2018 | J | 17 | $0.00 | A | 3,038 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $21.35 | Nov 21, 2018 | M | 98,636 | D | — | Dec 8, 2018 | Common Stock | 98,636 | 0 | D |
Explanation of responses
- F1Represents a "net exercise" of outstanding stock options due to expire on December 8, 2018, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on November 21, 2018.
- F2Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.